STRADB: A Protein Regulator of Cell Cycling and Brain Development

Target Name: STRADB

NCBI ID: G55437

STRADB

STRADB: A Protein Regulator of Cell Cycling and Brain Development

STRADB (PRO1038) is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Mutations in the STRADB gene have been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

In addition to its role in cell cycling, STRADB has also been shown to play a role in several other cellular processes that are important for brain development and function. For example, it has been shown to be involved in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels and helps to protect it from harmful substances.

STRADB has also been shown to be involved in the regulation of neurotransmitter release from neurons, which is important for the transmission of signals within the brain. In addition, it has been shown to play a role in the regulation of cell survival and proliferation, which is important for the development and maintenance of the brain.

Mutations in the STRADB gene have been linked to a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Studies have shown that individuals with certain genetic mutations, such as those that are associated with the development of Alzheimer's disease, have lower levels of STRADB in their brains.

In addition to its potential as a drug target, STRADB is also of interest as a potential biomarker for certain neurological disorders. For example, studies have shown that individuals with Alzheimer's disease have lower levels of STRADB in their brains compared to healthy individuals. This suggests that STRADB may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

In conclusion, STRADB is a protein that is expressed in various tissues throughout the body, including the brain, and plays a critical role in the regulation of cell cycling and other cellular processes. Mutations in the STRADB gene have been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. As a result, STRADB is of interest as a potential drug target and biomarker for these disorders. Further research is needed to fully understand the role of STRADB in the development and progression of these disorders.

Protein Name: STE20 Related Adaptor Beta

Functions: Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation (By similarity)

The "STRADB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STRADB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets